Introduction Li–Fraumeni syndrome, an autosomal dominant cancer predisposition syndrome caused by a pathogenic variant of TP53, tumor suppressor gene, leads to high risk from early childhood developing various types cancers. Here, we report case advanced ureteral in syndrome. Case presentation A 73 years-old female patient, who had been diagnosed genetically as syndrome; suffered chondrosarcoma...

PURPOSE We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS The medical records of 228 patients who underwent surgical resection and received adjuvant chemotherapy with trastuzumab for human epidermal growth factor receptor type 2 (HER2)-positive breast can...

The approval of immune checkpoint inhibitors (ICIs) has changed the treatment landscape in many aspects urothelial cancer (UC), both non-muscle-invasive bladder and muscle-invasive introduced concept long-term remission for some patients metastatic setting. Front-line chemotherapy remains superior at achieving initial control disease compared to front-line therapy. However, durable responses ar...

The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients as maintenance treatment, while the remaining patients received a placebo or observation only. Th...

Lung cancer has become a leading cause of cancer-related death in the world. Patient survival has improved with the introduction of new chemotherapy regimens and targeted drugs, but still, because of tumour progression or deterioration in performance status, a high percentage of patients do not receive more than one line of treatment. Given this situation, studies of maintenance therapies have ...

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular non-Hodgkin's lymphoma (fNHL) whose disease has responded to induction therapy with RTX plus cytotoxic chemotherapy (R-CTX) in accordance with the In...

Immune checkpoint inhibitors have revolutionized the treatment of urothelial carcinoma. They are now part standard care for locally advanced or metastatic Maintenance therapy with avelumab has been found to be most effective compared other immune inhibitors. To date, platinum-containing chemotherapy followed by maintenance is only regimen that significantly improved overall survival in patients...